Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) today announces that the company's annual report for the financial year 2020 has been published.
“Our HyNap technology is the first of its kind in the world and allows multiple pathways to success. During the year, we established a unique supply chain and strengthened the patent position concurrently with continued development of our first product candidate. I am therefore confident, that in 2021 we are well positioned to drive forward development of our pipeline product candidates with early entry dates and for which patent windows enable an advantageous US market launch.
Although we suffered a delay in the development of our first generic product candidate HyNap-Dasa, we could use the study results to expand the product portfolio with an improved version of the product. As a result, we now have two HyNap-Dasa product candidates, a generic version intended for the US market and an improved version for the worldwide market. Coupled with the progress of the HyNap-Nilo project, it demonstrates the usefulness of our strategy and the technology platform in creating multiple pathways to success,” says Per Andersson, CEO Xspray Pharma.
The annual report is attached and can also be downloaded from the company's website, www.xspraypharma.com